Skip to main content
Caplight Logo









Pykus Therapeutics Inc.

Pykus Therapeutics Inc.

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.pykustherapeutics.com/

Last Round

Grant

Mar 1, 2023

Total Funding Raised

$2.64M

Company Overview

Pykus Therapeutics Inc. is a clinical-stage medical technology company developing biodegradable polymers to provide solutions for unmet needs in vitreoretinal surgery.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

retinal detachment surgeryhydrogel sealantvitreoretinal surgerybiodegradable biomaterialvitrectomyophthalmic medical deviceretinal break repairsurgical sealantpost-operative recoverymedtechbiotechophthalmologyclinical-stage company

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pykus Therapeutics Inc. Comparables

Compare Pykus Therapeutics Inc. with similar companies based on industry and business-model similarity.

Pykus Therapeutics Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Geuder AG
71%
Bausch + Lomb Corporation
70%
BVI Medical
65%

Pykus Therapeutics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 1, 2023
SeedFeb 4, 2021
GrantNov 2, 2017
GrantMay 4, 2016

Key People

Founding team and executive leadership

Tomasz Stryjewski

Chief Scientific Officer, Director, Co-Founder

Founding Team

Pykus Therapeutics Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 10, 2025

    Initial data on novel retinal sealant PYK-2101 to be presented at Vail Vitrectomy 2025.

  • Feb 10, 2025

    Will present at the Vail Vitrectomy 2025 Meeting.

Pykus Therapeutics Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pykus Therapeutics Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pykus Therapeutics Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range12
Year Founded2016
Last FundingMar 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?